Dermata appoints Kyri Van Hoose as CFO; Thomas Insley resigns, becomes consultant

Dermata Therapeutics, Inc.

Kyri Van Hoose appointed SVP, CFO effective Sept 1, 2021; previously CFO at TEGA Therapeutics.
Thomas Insley resigned as CFO but remains as financial consultant via consulting agreement.
Van Hoose granted stock options for 75,000 shares at $5.39, vesting over 48 months from Oct 1, 2021.
Insley served as CFO for 6 years; transition supports continued development of DMT310 and DMT410.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kyri Van Hoose

Senior Vice President, Chief Financial Officer

DRMA · Dermata Therapeutics, Inc.

Effective: 2021-09-01
Filed: September 1, 2021, 7:59 PM ET

appointed Kyri Van Hoose as Senior Vice President, Chief Financial Officer, effective immediately.

Departed

Thomas Insley

Chief Financial Officer

DRMA · Dermata Therapeutics, Inc.

Effective: 2021-09-01
Successor: Kyri Van Hoose
Filed: September 1, 2021, 7:59 PM ET

On September 1, 2021, Thomas Insley resigned as Chief Financial Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Kyri Van Hoose was appointed as Senior Vice President, Chief Financial Officer at Dermata Therapeutics, Inc..

Action: appointed
Role: Senior Vice President, Chief Financial Officer

Exact text from the filing

appointed Kyri Van Hoose as Senior Vice President, Chief Financial Officer, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Thomas Insley resigned as Chief Financial Officer at Dermata Therapeutics, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On September 1, 2021, Thomas Insley resigned as Chief Financial Officer of the Company.

View on SEC.gov

Dermata Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-263316

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.